生物
血管生成
癌症研究
转移
趋化因子
三阴性乳腺癌
免疫学
肿瘤微环境
癌细胞
乳腺癌
癌症
细胞因子
免疫系统
遗传学
作者
Eun‐Sook Kim,Su-Min Nam,Hye Kyung Song,Seungeun Lee,Kyoungmee Kim,Hyun Lim,Hyunsook Lee,Kyu-Tae Kang,Yeo-Jung Kwon,Young-Jin Chun,So Yeon Park,Joohee Jung,Aree Moon
出处
期刊:Oncogene
[Springer Nature]
日期:2021-04-08
卷期号:40 (18): 3245-3259
被引量:21
标识
DOI:10.1038/s41388-021-01758-w
摘要
Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer with a poor prognosis for which no effective therapeutic measures are currently available. The present study aimed to investigate whether interactions with endothelial colony-forming cells (ECFCs) promote aggressive progression of TNBC cells. Herein, using an indirect co-culture system, we showed that co-culture increased the invasive and migratory phenotypes of both MDA-MB-231 TNBC cells and ECFCs. Through a cytokine antibody array and RT-PCR analysis, we revealed that co-culture markedly induced secretion of the chemokine C-C motif ligand (CCL)8 from ECFCs and that of interleukin (IL)-8 from MDA-MB-231 cells. CCL8 was crucial for ECFC-induced IL-8 secretion and invasion of MDA-MB-231 cells as well as for MDA-MB-231-enhanced MMP-2 secretion and angiogenesis of ECFCs. We suggest c-Jun as a transcription factor for CCL8-induced IL-8 expression in MDA-MB-231 cells. IL-8 was important for co-culture-induced CCL8 and MMP-2 upregulation and invasion of ECFCs. Notably, our findings reveal a positive feedback loop between CCL8 and IL-8, which contributes to the aggressive phenotypes of both ECFC and TNBC cells. Using an MDA-MB-231 cell-based xenograft model, we show that tumor growth and metastasis are increased by co-injected ECFCs in vivo. Increased expression of IL-8 was observed in tissues with bone metastases in mice injected with conditioned media from co-cultured cells. High IL-8 levels are correlated with poor recurrence-free survival in TNBC patients. Together, these results suggest that CCL8 and IL-8 mediate the crosstalk between ECFCs and TNBC, leading to aggravation of tumorigenicity in TNBC.
科研通智能强力驱动
Strongly Powered by AbleSci AI